Search Results
Aug 06, 2026, 16:20 ET MSC INCOME FUND ANNOUNCES SECOND QUARTER 2026 RESULTS
ending accrual for the accrued capital gains incentive fee(3) as of June 30, 2026, (ii) a $1.2 million increase in interest expense and (iii) a $0.4 million increase in base management fees, partially offset by a $0.6 million decrease in incentive fee on income, net of waivers. The increase
More news about: MSC Income Fund, Inc.
Aug 06, 2026, 16:15 ET Drilling Tools International Corp. Reports 2026 Second Quarter Results
depreciation and amortization, further adjusted for (i) goodwill and/or long-lived asset impairment charges, (ii) stock-based compensation expense, (iii) restructuring charges, (iv) transaction and integration costs related to acquisitions and (v) other expenses or charges to exclude certain items that
More news about: Drilling Tools International Corp.
Aug 06, 2026, 16:15 ET Corteva Announces Private Exchange Offers and Consent Solicitations for EIDP's 2.300% Senior Notes Due 2030, 5.125% Senior Notes Due 2032 and 4.800% Senior Notes Due 2033
to the Exchange Offers and Consent Solicitations or the Separation, including the receipt of the Requisite Consents, may not be satisfied or waived; (iii) that any event, change or other circumstance could give rise to the termination of the Exchange Offers and Consent Solicitations and/or the Separation;
More news about: Corteva Agriscience
Aug 06, 2026, 16:15 ET MATTHEWS INTERNATIONAL REPORTS RESULTS FOR FISCAL 2026 THIRD QUARTER
performance using the same tools that management uses to budget, forecast, make operating and strategic decisions, and evaluate historical performance, and (iii) otherwise provides supplemental information that may be useful to investors in evaluating the Company's results. The Company's calculations of its non-GAAP
More news about: Matthews International Corporation
Aug 06, 2026, 16:15 ET AMN HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS
healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market or economic conditions, (iii) the magnitude and duration of the effects of the post-COVID-19 pandemic environment or any future pandemic or health crisis on demand and supply trends,
More news about: AMN Healthcare Services, Inc.
Aug 06, 2026, 16:15 ET MAIN STREET ANNOUNCES SECOND QUARTER 2026 RESULTS
beginning of the comparable period of the prior year through our (i) at-the-market ("ATM") equity issuance program, (ii) dividend reinvestment plan and (iii) equity incentive compensation plans. The decreases in NII and DNII(1) on a per share basis in the second quarter of 2026 are after a net
More news about: Main Street Capital Corporation
Aug 06, 2026, 16:15 ET Post Holdings Reports Results for the Third Quarter of Fiscal Year 2026; Narrows Fiscal Year 2026 Outlook
assets, (ii) it presents a measure of corporate performance exclusive of Post's capital structure and the method by which the assets were acquired and (iii) it is a financial indicator of a company's ability to service its debt, as Post is required to comply with certain covenants and limitations that are
More news about: Post Holdings, Inc.
Aug 06, 2026, 16:10 ET RE/MAX HOLDINGS, INC. REPORTS SECOND QUARTER 2026 RESULTS
organic revenue growth as revenue growth from continuing operations excluding (i) revenue from Marketing Funds, (ii) revenue from acquisitions, and (iii) the impact of foreign currency movements. The Company defines revenue from acquisitions as the revenue generated from the date of an acquisition to
More news about: RE/MAX Holdings, Inc.
Aug 06, 2026, 16:09 ET Saul Centers, Inc. Reports Second Quarter 2026 Earnings
policy, which may lead to a disruption of, or lack of access to, sources of funding and rising inflation, (ii) the ability of our tenants to pay rent, (iii) our reliance on shopping center "anchor" tenants and other significant tenants, (iv) our substantial relationships with members of the B. F. Saul Company
More news about: Saul Centers, Inc.
Aug 06, 2026, 16:05 ET Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook
replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements; (iii) Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock-based
More news about: Shoulder Innovations
Aug 06, 2026, 16:05 ET Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
"Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release. Second Quarter Results
More news about: Amphastar Pharmaceuticals, Inc.
Aug 06, 2026, 16:05 ET Csquare Reports Record Second Quarter 2026 Results
release.Adjusted EBITDAWe define Adjusted EBITDA as net (loss) income, excluding (i) income taxes, (ii) interest expense, (iii) depreciation and amortization, (iv) gain on lease modification, (v) loss on extinguishment of debt, (vi) bargain purchase gain, (vii) other income (loss),
More news about: Csquare, Inc.
Aug 06, 2026, 16:05 ET CleanSpark Reports Third Fiscal Quarter 2026 Results
performance, and for which the accounting requires management judgment, and the resulting expenses could vary significantly in comparison to other companies; (iii) non-cash impairment losses related to long-lived assets; (iv) realized gains and losses on sales of equity securities, the amounts of which are directly
More news about: CleanSpark, Inc.
Aug 06, 2026, 16:05 ET MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
attributable to (i) $0.1 million in higher consulting expenditures, (ii) approximately $0.1 million in higher employee compensation and benefits costs, and (iii) $0.1 million in higher other G&A expenses, which was primarily related to higher franchise tax expenses.Total Operating
More news about: MetaVia Inc.
Aug 06, 2026, 16:05 ET Aflac Incorporated Announces Second Quarter 2026 Results, Declares Third Quarter Dividend
foreign currency and interest rate derivatives associated with certain investment strategies, which are both reclassified to net investment income, and iii) the impact of interest from derivatives associated with notes payable, which is reclassified to interest expense as a component of total adjusted expenses.
More news about: Aflac Incorporated
Aug 06, 2026, 16:03 ET Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company
business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to Health Catalyst's technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners, clients reducing or eliminating their spend with
More news about: Health Catalyst
Aug 06, 2026, 16:03 ET BioLife Solutions Reports Second Quarter 2026 Financial Results
approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials.Our
More news about: BioLife Solutions, Inc.
Aug 06, 2026, 16:01 ET BRC Group Holdings, Inc. Reports Second Quarter 2026 Financial Results
gains (losses), net and fair value adjustments on loans, less fixed income spread and trading gains attributable to variable rate transaction spread; (iii) excluding in the case of Adjusted EBITDA, net interest expense, provisions for or benefit from income taxes, depreciation, amortization, restructuring
More news about: BRC Group Holdings, Inc.
Aug 06, 2026, 16:01 ET HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the Company's ongoing business operations and (iii) whether or not the Company expects it to occur as part of the Company's normal business on a regular basis. Non-GAAP financial measures do not have
More news about: Halozyme Therapeutics, Inc.
Aug 06, 2026, 16:00 ET Instacart Announces Second Quarter 2026 Financial Results
Margin. We define Adjusted EBITDA as net income (loss), adjusted to exclude (i) provision for (benefit from) income taxes, (ii) interest income, (iii) other (income) expense, net, (iv) depreciation and amortization expense, (v) stock-based compensation expense, (vi) payroll taxes related to stock-based
More news about: Maplebear Inc. dba Instacart
Aug 06, 2026, 14:55 ET LUCA INTERSECTS 184 METRES OF 1.2 G/T GOLD, 72 G/T SILVER, 0.4% COPPER, 0.5% LEAD AND 1.7% ZINC AT THE LARGO NORTE ZONE, CAMPO MORADO MINE
will expire five years from the date of their issuance. The Options will vest as follows: (i) 33% on July 29, 2026; (ii) 33% January 29, 2027; and (iii) the balance on July 29, 2027. The RSU's will vest on July 29, 2027. Qualified PersonThe technical information contained in this
More news about: Luca Mining Corp.
Aug 06, 2026, 12:04 ET Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
(GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval
More news about: Northwest Biotherapeutics, Inc.
Aug 06, 2026, 11:58 ET Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
(GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval
More news about: Northwest Biotherapeutics, Inc.
Aug 06, 2026, 10:31 ET The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
and ADEPT-4 Phase III studies are expected to deliver topline results for Alzheimer's disease psychosis in 2026. If these studies are successful and regulatory approvals are secured, COBENFY could reach the market as early as 2027. In Alzheimer's disease agitation, the Phase III ADAGIO-2 trial is
More news about: DelveInsight Business Research, LLP
Aug 06, 2026, 10:07 ET SueWallSt Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN
Investor Securities Recovery ERISA ReviewThe complaint alleges Regeneron presented an overly optimistic picture of its Phase III Fianlimab-Libtayo Study disclosures while minimizing the risk that a prolonged slowdown in progression-free survival event accrual reflected deeper statistical
More news about: SueWallSt.com